Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Short term Debt (2020 - 2025)

Puma Biotechnology's Short term Debt history spans 5 years, with the latest figure at $22.5 million for Q4 2025.

  • For Q4 2025, Short term Debt fell 50.31% year-over-year to $22.5 million; the TTM value through Dec 2025 reached $22.5 million, down 50.31%, while the annual FY2025 figure was $22.5 million, 50.31% down from the prior year.
  • Short term Debt reached $22.5 million in Q4 2025 per PBYI's latest filing, down from $33.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $45.3 million in Q1 2024 to a low of $11.3 million in Q2 2023.
  • Average Short term Debt over 4 years is $33.8 million, with a median of $34.0 million recorded in 2023.
  • Peak YoY movement for Short term Debt: surged 300.01% in 2024, then tumbled 50.31% in 2025.
  • A 4-year view of Short term Debt shows it stood at $31.4 million in 2021, then rose by 8.17% to $34.0 million in 2023, then skyrocketed by 33.33% to $45.3 million in 2024, then crashed by 50.31% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Short term Debt are $22.5 million (Q4 2025), $33.7 million (Q3 2025), and $34.0 million (Q2 2025).